Background The efficacy of endothelin receptor antagonists (ERA) in reducing proteinuria in patients with IgA nephropathy (IgAN) has been validated in phase III clinical trials. Ambrisentan, as a selective ERA receptor antagonist, protects the kidneys by antagonizing endothelin. Our study aimed to investigate the efficacy and safety of ambrisentan in patients with IgAN. Methods Medical records and follow-up data of IgAN patients treated with ambrisentan in our hospital from November 2022 to December 2023 were collected. Follow-up assessments were conducted at weeks 4, 8, and 12. The primary outcomes were 24-hour urinary protein, 24-hour urinary protein change rate estimated glomerular filtration rate (eGFR), and drug safety monitoring. Results A total of 147 IgAN patients were included in the study. The baseline 24h urinary protein level was 1.16 [0.74,1.99] g/day. Compared to baseline, the urinary protein level was 0.7 (0.38 to 1.32) g/day at week 4, with a reduction of 40.5%, Z=-8.157,P＜0.001. At week 8, the urinary protein level was 0.60 (0.43 to 1.44) g/day, with a reduction of 40.25%, Z=-5.866, P＜0.001. At week 12, the urinary protein level was 0.66 (0.43 to 1.43) g/day, with a reduction of 38.9%, Z=-5.238, P＜0.001.There was no significant difference in the rate of 24h UP reduction among subgroups stratified by gender, eGFR, or concomitant medication including steroids, immunosuppressants, and Renin-Angiotensin-Aldosterone System inhibitor (RAASi). eGFR remained stable during the 12-week follow-up period. Ambrisentan was well tolerated in the follow-up patients, with two patients discontinuing treatment due to edema or impaired liver function. Conclusion Ambrisentan can reduce proteinuria in patients with IgAN and is well tolerated.
[1]ROVIN B H, ADLER S G, BARRATT J, et al.Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases[J].Kidney Int, 2021, 100(4):753-779
[2]REICH H N, TROYANOV S, SCHOLEY J W, et al.Remission of proteinuria improves prognosis in IgA nephropathy[J].J Am Soc Nephrol, 2007, 18(12):3177-3183
[3]KOHAN D E, BARTON M.Endothelin and endothelin antagonists in chronic kidney disease[J].Kidney Int, 2014, 86(5):896-904
[4]HELAL I, FICK-BROSNAHAN G M, REED-GITOMER B, et al.Glomerular hyperfiltration: definitions,mechanisms and clinical implications[J].Nat Rev Nephrol, 2012, 8(5):293-300
[5]TONNEIJCK L, MUSKIET M H, SMITS M M, et al.Glomerular Hyperfiltration in Diabetes: Mechanisms,Clinical Significance,and Treatment[J].J Am Soc Nephrol, 2017, 28(4):1023-1039
[6]KOMERS R, PLOTKIN H.Dual inhibition of renin-angiotensin-aldosterone system and endothelin-1 in treatment of chronic kidney disease[J].Am J Physiol Regul Integr Comp Physiol, 2016, 310(10):R877-884
[7]HEERSPINK H J L, PARVING H H, ANDRESS D L, et al.Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind,randomised,placebo-controlled trial[J].Lancet, 2019, 393(10184):1937-1947
[8]MARTíNEZ-DíAZ I, MARTOS N, LLORENS-CEBRIà C, et al.Endothelin Receptor Antagonists in Kidney Disease,[J].[J]. Int J Mol Sc, 2023, 24(4):133-140
[9]RHEAULT M N, ALPERS C E, BARRATT J, et al.Sparsentan versus Irbesartan in Focal Segmental Glomerulosclerosis[J].N Engl J Med, 2023, 389(26):2436-2445
[10]HEERSPINK H J L, RADHAKRISHNAN J, ALPERS C E, et al.Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised,double-blind,active-controlled clinical trial[J].Lancet, 2023, 401(10388):1584-1594
[11].HEERSPINK H J L, RADHAKRISHNAN J, ALPERS C E, et al. Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial [J]. Lancet, 2023, 401(10388): 1584-1594.
[12]LI H F, WANG J X, XIE Z F, et al.Bosentan and ambrisentan in the treatment of idiopathic pulmonary fibrosis: a meta-analysis[J].Eur Rev Med Pharmacol Sci, 2024, 28(3):1183-1193
[13]KOHAN D E, BARRATT J, HEERSPINK H J L, et al.Targeting the Endothelin A Receptor in IgA Nephropathy[J].Kidney Int Rep, 2023, 8(11):2198-2210
[14]RAINA R, CHAUVIN A, CHAKRABORTY R, et al.The Role of Endothelin and Endothelin Antagonists in Chronic Kidney Disease[J].Kidney Dis (Basel), 2020, 6(1):22-34
[15]Ambrisentan [M].LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. Bethesda (MD); National Institute of Diabetes and Digestive and Kidney Diseases. 2012.
[16]DHAUN N, LILITKARNTAKUL P, MACINTYRE I M, et al.Urinary endothelin-1 in chronic kidney disease and as a marker of disease activity in lupus nephritis[J].Am J Physiol Renal Physiol, 2009, 296(6):F1477-1483
[17]KOOMEN J V, STEVENS J, MOSTAFA N M, et al.Determining the optimal dose of atrasentan by evaluating the exposure-response relationships of albuminuria and bodyweight[J].Diabetes Obes Metab, 2018, 20(8):2019-2022
[18]KIM S-G, VO N, LEE S-H, et al.FC052: Atrasentan for the Treatment of IGA Nephropathy: Interim Results from the Affinity Study 2022, 37.[J].[J]. Nephrology Dialysis Transplantation, 2022, 37(1):1-4
[19]ROVIN B H, BARRATT J, HEERSPINK H J L, et al.Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised,active-controlled,phase 3 trial[J].Lancet, 2023, 402(10417):2077-2090
[20]顾思捷, 范瑛, 汪年松.内皮素受体拮抗剂治疗糖尿病肾病研究进展[J].世界临床药物, 2023, 44(01):8-14
[21]DHAUN N, MACINTYRE I M, MELVILLE V, et al.Effects of endothelin receptor antagonism relate to the degree of renin-angiotensin system blockade in chronic proteinuric kidney disease[J].Hypertension, 2009, 54(3):e19-20
[22]BENIGNI A, CORNA D, MAFFI R, et al.Renoprotective effect of contemporary blocking of angiotensin II and endothelin-1 in rats with membranous nephropathy[J].Kidney Int, 1998, 54(2):353-359
[23]GAGLIARDINI E, CORNA D, ZOJA C, et al.Unlike each drug alone,lisinopril if combined with avosentan promotes regression of renal lesions in experimental diabetes[J].Am J Physiol Renal Physiol, 2009, 297(5):F1448-1456
[24]HEERSPINK H J L, KIYOSUE A, WHEELER D C, et al.Zibotentan in combination with dapagliflozin compared with dapagliflozin in patients with chronic kidney disease (ZENITH-CKD): a multicentre,randomised,active-controlled,phase 2b,clinical trial[J].Lancet, 2023, 402(10416):2004-2017
[25]ZHOU Y, CHI J, HUANG Y, et al.Efficacy and safety of endothelin receptor antagonists in type 2 diabetic kidney disease: A systematic review and meta-analysis of randomized controlled trials[J].Diabet Med, 2021, 38(1):e14411-e14415
